Wednesday, August 4, 2021

South SF-Based Sonoma Biotherapeutics Raises $265 Million

 By David Gross

Boston dominated big fundings earlier this year, but the Bay Area is coming on strong in Q3, having led all markets in life sciences VC raised in July.  Cell therapy developer Sonoma Biotherapeutics is the latest biotech company in the region to pull in a multi-hundred million dollar round, having just raised a $265 million Series B in a syndicate that included GV (formerly Google Ventures), ARCH, 8VC, and Alexandria Venture Investments.

Sonoma is headquartered at Alexandria's 400 East Jamie Court property in South City, in the same building where Lyell Immunopharma signed a lease with an initial base rent of $66 in 2019.   

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.